UX-001SA-ER: Completed Phase II enrollment

Ultragenyx completed enrollment of 45 patients ages 18-65 years in a double-blind, placebo-controlled, international Phase II trial evaluating 3,000 and 6,000 mg UX001 daily for 48 weeks. Patients rec...